September 2001
Worldwide Biotech;Sep2001, Vol. 13 Issue 9, p1
Trade Publication
No abstract available.


Related Articles

  • ID Biomedical gains NIH grant to develop nasally delivered plague vaccine.  // PharmaWatch: Biotechnology;November 2004, Vol. 3 Issue 11, p5 

    Reports that ID Biomedical has been awarded grant by the U.S. National Institutes of Health to develop a nasally delivered plague vaccine based on its proprietary, intranasal, Proteosome adjuvant/delivery technology. Aim to develop a sub-unit plague vaccine using a recombinant plague antigen,...

  • Phase II data shows strong immunogenicity for ID Biomedical's FluINsure.  // PharmaWatch: Biotechnology;August 2003, Vol. 2 Issue 8, p7 

    Focuses on the clinical trials for FlulNsure, an intranasal, non-live, influenza vaccine developed by ID Biomedical Corp. Patients enrolled in the study; Presentation of the clinical study of FlulNsure; Evaluation on the efficacy of the influenza vaccine.

  • Infection control Update.  // Healthcare Purchasing News;Feb2005, Vol. 29 Issue 2, p26 

    Presents news briefs on the health care industry as of February 2005. Information on the safety-engineered BD Integra 1ml Retracting Tuberculin and Insulin Syringe released by Becton, Dickenson, and Company; Clearance received by ID Biomedical from the U.S. Food and Drug Administration to run a...

  • EXPANDED HUMAN TESTING OF NASAL FLU VACCINE BEGINS.  // Worldwide Biotech;Jul2001, Vol. 13 Issue 7, p2 

    Announces the start of the expanded human safety and immunogenecity testing of the intranasal influenza vaccine from ID Biomedical Corporation.

  • News update.  // Materials Management in Health Care;Feb99, Vol. 8 Issue 2, p13 

    Reports on ID Biomedical Corp.'s plans in marketing the Velogene test for resistant bacterium.

  • Canadian company to develop mock pandemic vaccine. Eggertson, Laura // CMAJ: Canadian Medical Association Journal;3/1/2005, Vol. 172 Issue 5, p623 

    Focuses on a mock pandemic vaccine being developed by Vancouver-based ID Biomedical Corp. to protect people against H5N1 influenza in British Columbia. Utilization of reverse genetics technology; Requirements for the phase II clinical trials; Comment from Michele Roy, spokesperson for ID...

  • Innovative vaccine targets streptococci. Posey, L. Michael // Pharmacy Today;Nov2005, Vol. 11 Issue 11, p10 

    The article reports on a study that focuses on the safety and immunogenicity of a 26-valent vaccine developed by ID Biomedical Corp. The study was published in the October 15 issue of "Clinical Infectious Diseases." Strep throat is a common childhood infection caused by group A streptococcus...

  • Vancouver company launches new superbug test. Kent, Heather // CMAJ: Canadian Medical Association Journal;9/21/99, Vol. 161 Issue 6, p679 

    Reports about a test for detecting methicillin-resistant Staphylococcus aureus (MRSA) from the Canadian company I.D. Biomedical Corporation. Test approval by the United States Food and Drug Administration and expected approval by Health Canada; Comments by the Dr. Tony Holler, the company's...

  • Mergers & Acquisitions Update.  // PharmaWatch: Biotechnology;Jan2006, Vol. 5 Issue 1, p18 

    This article presents an update on merging and acquisitions in the pharmaceutical industry. American Pharmaceutical Partners will merge with its parent company American BioScience in order to form a fully integrated, global biopharmaceutical company and will be named as Abraxis BioScience....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics